Michaela Petrini

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

Natalie Staplin, Richard Haynes, PK Judge et al. · The Lancet Diabetes & Endocrinology · 2023 · 74 citations · Full text

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from the EMPEROR-Preserved Trial

Abhinav Sharma, João Pedro Ferreira, Faı̈ez Zannad et al. · European Journal of Heart Failure · 2023 · 59 citations · Full text

Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system

Todd C. Villines, Azhar Ahmad, Michaela Petrini et al. · European Heart Journal - Cardiovascular Pharmacotherapy · 2018 · 24 citations · Full text

Pharmacokinetics/Pharmacodynamics of Dabigatran 75 mg Twice Daily in Patients With Nonvalvular Atrial Fibrillation and Severely Impaired Renal Function

Jack L. Martin, Habib Esmaeili, Raymond C. Manuel et al. · Journal of Cardiovascular Pharmacology and Therapeutics · 2018 · 15 citations

Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds

Alex C. Spyropoulos, Bríain ó Hartaigh, Zhun Cao et al. · Clinical and Applied Thrombosis/Hemostasis · 2022 · 12 citations · Full text